Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

This study has been completed.
Sponsor:
Collaborator:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00328198
First received: May 18, 2006
Last updated: February 10, 2014
Last verified: February 2014
  Purpose

This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who have been previously treated.


Condition Intervention Phase
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Biological: Alemtuzumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Number of Participants With Best Disease Response as Determined by the Independent Response Review Panel (IRRP) [ Time Frame: up to 44 weeks ] [ Designated as safety issue: No ]
    Participants were evaluated by the IRRP according to National Cancer Institute (NCI) 1996 response criteria. The best response observed during the study is summarized. Response categories include Complete Response (CR) with normal physical exam, marrow cells and blood values, Partial Response (PR) with a >= 50% decrease from baseline in lymphocytes, lymphadenopathy and liver or spleen exam, Stable Disease (SD) without significant progression from baseline, or Progressive Disease (PD) with increased size/number of nodes, size of liver or spleen, increase in lymphocytes, aggressive histology.

  • Percentage of Participants Who Had an Overall Response (OR) as Determined by the Independent Response Review Panel (IRRP) [ Time Frame: up to 44 weeks ] [ Designated as safety issue: No ]
    Participants were evaluated by the IRRP according to National Cancer Institute (NCI) 1996 response criteria. The percentage of participants whose best response observed during the study was either a Complete Response (CR) or a Partial Response (PR). Overall Response (OR) = CR + PR. A Complete Response (CR) exhibits a normal physical exam, marrow cells and blood values. A Partial Response (PR) has a >= 50% decrease from baseline in lymphocytes, lymphadenopathy and liver or spleen exam.


Secondary Outcome Measures:
  • Kaplan-Meier Estimates of Progression Free Survival as Determined by the Independent Response Review Panel (IRRP) [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]

    Progression-free survival was defined as the number of days from the date of first treatment to the date of first objective documentation of progressive disease (PD) as determined by the IRRP, or death due to any cause. Results are expressed in months.

    Progressive Disease (PD) was defined as an increase in size/number of nodes, size of liver or spleen, increase in lymphocytes, or aggressive histology.


  • Kaplan-Meier Estimates of Duration of Response as Determined by the Independent Response Review Panel (IRRP) [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]

    Duration of response was analyzed for participants who achieved a complete response (CR) or partial response (PR) and was defined as the number of days from the first date of documented response to the date of progressive disease (PD) as determined by IRRP or death due to any cause. Results are stated in months.

    Progressive Disease (PD) was defined as an increase in size/number of nodes, size of liver or spleen, increase in lymphocytes, or aggressive histology.


  • Kaplan-Meier Estimates of Overall Survival [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    Overall survival was defined as the time in days from the date of first treatment to the date of death due to any cause for all participants. Results are stated in months.

  • Participants With a Minimal Residual Disease (MRD) Status of Negative [ Time Frame: 44 weeks ] [ Designated as safety issue: No ]
    MRD negativity represents a very positive response outcome. MRD negativity in this report was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. All patients are evaluated for treatment response based on National Cancer Institute Working Group (NCIWG) criteria. Of patients who have achieved a clinical complete response (CR) or partial response (PR) that met National Cancer Institute Working Group (NCIWG) criteria of CR except blood recovery, a bone marrow sample was taken for flow cytometry measure of MRD negativity.

  • Participants With Treatment-Emergent Adverse Events (TEAE) [ Time Frame: up to 18 weeks of treatment plus 45 days ] [ Designated as safety issue: Yes ]
    Number of participants with treatment-emergent adverse events (TEAEs). AEs were graded by the investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and were assessed for relatedness to study treatment (5 point scale from 'not related' to 'definitely related') and severity (5 point scale with grade 5 being most severe). Categories reported include participant counts for treatment-emergent AEs, injection site reactions, AEs for infections, serious AEs, AEs causing discontinuation of study drug(s), deaths and severity.


Enrollment: 86
Study Start Date: May 2006
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose escalation
Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
Biological: Alemtuzumab

Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.

Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study.

Other Name: Campath®, MabCampath®
Experimental: No escalation
Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
Biological: Alemtuzumab

Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.

Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration.

Other Name: Campath®, MabCampath®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A diagnosis of B-cell chronic lymphocytic leukemia (B-CLL); according to the National Cancer Institute Working Group (NCI WG) Criteria.
  • World Health Organization (WHO) performance status of 0, 1, or 2.
  • Life expectancy ≥ 12 weeks.
  • Previous therapy with at least one but no more than 5 regimens (single agent or combination regimen). One therapy regimen is defined as consecutive, contiguous cycles of the same drug(s) with no treatment interruptions lasting > 3 months.
  • Patient requires treatment for CLL per the following criteria: -Rai stage III or IV; -Rai stage 0-II with at least one of the following - evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia; Massive (i.e. greater than 6 cm below the left costal margin) or progressive splenomegaly; Progressive lymphocytosis with an increase of greater than 50% over a 2-month period or an anticipated doubling time of less than 6 months; Lymphocyte count > 100*10^9/L; B symptoms.
  • More than 3 weeks since prior chemotherapy. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
  • More than 3 weeks since using investigational agents. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
  • Serum creatinine and conjugated (direct) bilirubin less than or equal to 2 times the institutional upper limit of normal (ULN) unless secondary to direct infiltration of the liver with CLL.
  • Female patients with childbearing potential must have a negative pregnancy test (serum or urine) within 2 weeks of first dose of study drug(s). All patients must agree to use an effective contraceptive method while on study treatment, if appropriate, and for a minimum of 6 months following study therapy.
  • Signed, written informed consent (in the US, includes The Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization)

Exclusion Criteria:

  • Positive Coombs test and evidence of active hemolysis.
  • Platelet count less than 50*10^9/L without splenomegaly.
  • History of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanized monoclonal antibodies.
  • Previously treated with CAMPATH.
  • Previous bone marrow transplant.
  • Known central nervous system (CNS) involvement with B-CLL
  • Active infection, including human immunodeficiency virus (HIV) positive.
  • Active second malignancy.
  • Recent documented history (within 2 years) of active tuberculosis (TB), current active TB infection, currently receiving anti-tuberculous medication (e.g., INH, rifampin, streptomycin, pyrazinamide, or others).
  • Active hepatitis or a history of prior viral hepatitis B or hepatitis C, or positive hepatitis B serologies. Patients with a positive hepatitis B surface antibody (HBsAb) test with a documented history of prior hepatitis B immunization are eligible as long as other criteria are met (i.e. negative tests for: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) and hepatitis C virus antibody (HCVAb)).
  • Other severe, concurrent diseases (e.g., cardiac or pulmonary disease), mental disorders, or major organ malfunction (liver, kidney) that could interfere with the patient ability to participate in the study.
  • Pregnant or nursing women.
  • Cytomegalovirus (CMV) positive by polymerase chain reaction (PCR) (above the level of detection). A patient that is PCR positive will require treatment to reduce the viral load to a non-detectable level; but such a patient may be considered for study entry once the infection has been treated.
  • Medical condition requiring chronic use of oral corticosteroids at a dose higher than physiologic replacement.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00328198

Locations
United States, California
Moores Cancer Center
La Jolla, California, United States, 92093-0820
Wilshire Oncology Medical Group
La Verne, California, United States, 91750
United States, Colorado
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80045
Rocky Mountain Cancer Centers
Colorado Springs, Colorado, United States, 80909
United States, Mississippi
North Mississippi Hematology & Oncology Associates, Ltd.
Tupelo, Mississippi, United States, 38801
United States, Ohio
Mid Ohio Oncology Hematology, Inc.
Columbus, Ohio, United States, 43213
United States, Texas
Joe Arrington Cancer Center
Lubbock, Texas, United States, 79140
Belgium
Academisch Ziekenhuis der Vrije Universiteit Brussel
Brussels, Belgium, 1090
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Gent, Belgium, B-9000
Universitair Ziekenhuis Leuven
Leuven, Belgium, B-3000
Czech Republic
University Hospital Brno
Brno, Czech Republic, 625 00
University Hospital Hradec Kralove (UH HK)
Hradec Kralove, Czech Republic
France
Hopital Hotel-Dieu
Clermont-Ferrand, France, 63058
Hopital Claude Huriez
Lille, France, 59037
Hopital Hotel-Dieu, CHU de Nantes-Service d'Hematologie Clinique
Nantes, France
Serbia
Institute of Hematology, Clinical Centre of Serbia
Belgrade, Serbia, 11 000
Clinic of Hematology, Clinical Centre Vojvodina Novi Sad
Novi Sad, Serbia, 21000
United Kingdom
Leeds General Infirmary
Leeds, United Kingdom, LS1 3EX
Royal Liverpool and Broadgreen Hospitals
Liverpool, United Kingdom, L7 8XP
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Genzyme, a Sanofi Company
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided

Responsible Party: Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT00328198     History of Changes
Other Study ID Numbers: CAM203, 2005-005074-69
Study First Received: May 18, 2006
Results First Received: June 25, 2012
Last Updated: February 10, 2014
Health Authority: United States: Food and Drug Administration
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Sanofi:
CAMPATH
Alemtuzumab
Leukemia
MabCampath
Chronic
Subcutaneous
CLL
C-CLL
Relapsed
Refractory
Chronic Lymphocytic Leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Alemtuzumab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014